TYMS and cancer: Previous publications have shown that inhibition of dUTPase sensitises cancer cells to TS-targeting chemotherapies10–14,24,25, however, this is the first paper demonstrating that directly targeting dUTPase can sensitise cancer cells to anthracyclines and simulated chemotherapy regimens containing both fluoropyrimidines and anthracyclines.